GLP‑1 drugs like Ozempic show promise for more than weight loss, but what's science vs. hype?
You've probably heard of Ozempic or Wegovy. These are the injectable drugs that have become household names for weight loss and diabetes.
Jun 2, 2026
0
6
Amino Acids, Peptides, and Proteins: News and Research on Gastric Inhibitory Polypeptide
MeSH tree: D12.644.548.275
How digital platforms and policy shifts reshape GLP-1 affordability
A News and Perspectives report on emerging pharmaceutical access models in the United States has been published in the Journal of Medical Internet Research. In "Affordable GLP-1? When Digital Platforms Meet Policy Reform", ...
Jun 1, 2026
0
4
Weight loss drugs risk widening health inequalities, warn researchers
Drugs such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro) are transforming obesity treatment, but without affordable, healthy food and appropriate support, they could widen health inequalities in the UK, according ...
Jun 1, 2026
0
4
Tirzepatide superior to intensified conventional care for early type 2 diabetes
Tirzepatide is superior to intensified conventional care (ICC) for adults with early type 2 diabetes (T2D) uncontrolled with metformin, according to a study published online May 26 in the Annals of Internal Medicine.
May 27, 2026
0
3
EU regulator approves pill form of Novo Nordisk's Wegovy weight loss drug
Novo Nordisk has obtained approval for the pill form of its popular Wegovy anti-obesity drug in the European Union, the bloc's medicines regulator said on Friday.
May 22, 2026
0
9
Which patients benefit most from tirzepatide GLP-1 for obesity and obstructive sleep apnea?
Tirzepatide GLP-1 medication is known to improve sleep apnea for people with both obstructive sleep apnea (OSA) and obesity, but not all patients benefit equally. Now, new research presented at the 2026 ATS International ...
May 19, 2026
0
9
Most weight loss achieved using injectable obesity drugs can be maintained by switching to orforglipron, study shows
New research presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May) and published in Nature Medicine shows that most weight loss achieved using the injectable obesity drugs tirzepatide or ...
May 13, 2026
0
7
Continuing tirzepatide at full dose helps preserve weight loss over 112 weeks
New research presented at the European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12–15 May) and published in The Lancet shows that people who have lost weight using the maximum tolerated dose (MTD) of tirzepatide ...
May 13, 2026
0
19
Study shows benefits in obesity-linked conditions of losing more weight with GLP-1 treatment
New research presented at the European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12–15 May) shows that, following treatment for obesity or diabetes or both, using incretin-based drugs, losing more weight versus less ...
May 9, 2026
0
7
A new Medicare option for weight loss drugs: What older Americans should know
Starting in July, Medicare beneficiaries may be able to get a GLP-1 prescription for weight loss for $50 a month. It's a notable shift for Medicare, which has long been barred from covering weight loss treatments.
May 8, 2026
0
13
